TrialCurveCEPHEUS: reconstructed Kaplan–Meier curves
Daratumumab plus bortezomib, lenalidomide and dexamethasone for transplant-ineligible or transplant-deferred newly diagnosed multiple myeloma: the randomized phase 3 CEPHEUS trial. Curves rebuilt as patient-level data (Guyot 2012) and checked against the statistics printed on the figure.
| Publication | Nat Med. 2025 Feb 5;31(4):1195–202. doi: 10.1038/s41591-024-03485-7 |
|---|---|
| DOI | 10.1038/s41591-024-03485-7 |
| Registry | NCT03652064 |
| Phase | Phase 3 |
| Conditions | Multiple Myeloma |
| Interventions | Daratumumab, Bortezomib, Lenalidomide, Dexamethasone |
| Sponsor | Janssen Research & Development, LLC |
| Enrolment | 395 |
| Source licence | Figure published under CC BY 4.0 |
Progression-free survival — Intention-to-treat population
From figure panel · validated against the values printed on the figure · curve source: pixel measurement confirmed by vision model
Reconstructed from the published curve. Median: D-VRd not reached; VRd 52.5 months. Survival at 18 months: D-VRd 86%; VRd 82%. Hazard ratio D-VRd vs VRd 0.58 (95% CI 0.42–0.81).
| Arm | N | Events | Median (Months) |
|---|---|---|---|
| D-VRd | 197 | 61 | not reached |
| VRd | 198 | 90 | 52.5 |
- D-VRd vs VRd: reconstructed HR 0.58 (95% CI 0.42–0.81)
Landmark survival (reconstructed)
| Time | D-VRd | VRd |
|---|---|---|
| 6 mo | 93.8% | 95.3% |
| 12 mo | 89.6% | 89.1% |
| 18 mo | 86.4% | 82.3% |
| 24 mo | 80.5% | 77.1% |
| 36 mo | 75.6% | 62.3% |
| 48 mo | 70.4% | 53.9% |
| 60 mo | — | 48.1% |
Checks against the published figure
- hazard ratio (direction inferred): printed 0.57, reconstructed 0.585 pass
Overall survival — Intention-to-treat population
From figure panel · curves cross-checked by two independent readings · curve source: pixel measurement confirmed by vision model
Reconstructed from the published curve. Median: D-VRd not reached; VRd not reached. Survival at 18 months: D-VRd 87%; VRd 89%. Hazard ratio VRd vs D-VRd 1.13 (95% CI 0.78–1.65).
| Arm | N | Events | Median (Months) |
|---|---|---|---|
| D-VRd | 197 | 51 | not reached |
| VRd | 198 | 59 | not reached |
- VRd vs D-VRd: reconstructed HR 1.13 (95% CI 0.78–1.65)
Landmark survival (reconstructed)
| Time | D-VRd | VRd |
|---|---|---|
| 6 mo | 95.9% | 96.4% |
| 12 mo | 90.8% | 92.2% |
| 18 mo | 87.1% | 88.5% |
| 24 mo | 84.0% | 85.9% |
| 36 mo | 78.1% | 78.3% |
| 48 mo | 75.9% | 71.8% |
| 60 mo | — | 68.5% |
About these data
Pseudo-IPD reproduces the published curves and numbers at risk; the rows are not real patients. Cite the publication (DOI above) and TrialCurve. The source figure is © the authors (CC BY 4.0); the charts here are redrawn from the reconstruction.
Related trials
- CPT-MM301: Overall survival; Progression-free survival (Independent Assessment Committee)
- Mesenchymal stromal cells for steroid-resistant acute GVHD: Cumulative incidence of leukemia relapse; Non-relapse mortality (NRM); Overall survival; c
- ADMYRE: Overall survival; Progression-free survival with PD confirmation by investigator's assessm
- CLL12: Event-free survival (EFS); Overall survival (OS)
- Acalabrutinib vs chlorambucil + rituximab in CLL (Asian phase 3): BICR-assessed duration of response; BICR-assessed progression-free survival; Overall survi
Need reconstructed data for other trials? Upload any Kaplan–Meier figure, or ask about the TrialCurve oncology library.
Reconstruct a figure Browse all trials